Megan S. Keiser

CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo

Alex Mas Monteys, Shauna Ebanks, Megan S. Keiser et al. · Molecular Therapy · 2017 · 302 citations · Full text

Engineering, In Vivo Gene Therapy, Genetics +18

Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy

Megan S. Keiser, Ryan L. Boudreau, Beverly L. Davidson · Molecular Therapy · 2014 · 79 citations · Full text

Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain

Megan S. Keiser, Paul T. Ranum, Carolyn M. Yrigollen et al. · Nature Medicine · 2021 · 70 citations · Full text

Neurovirology, Immunology, Cell Death +7

APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease

Rosemary J. Jackson, Megan S. Keiser, Jonah C Meltzer et al. · Molecular Therapy · 2024 · 60 citations · Full text

Neurochemical Biomarkers, Synaptic Signaling, Social Sciences +23

RNAi prevents and reverses phenotypes induced by mutant human ataxin‐1

Megan S. Keiser, Alejandro Mas Monteys, Romuald Corbau et al. · Annals of Neurology · 2016 · 53 citations · Full text